Seeking Approval: Present and Future Therapies for Pemphigus Vulgaris

Overview

Journal Curr Opin Investig Drugs

Specialties Infectious Diseases
Pharmacology

Date 2008 May 10

PMID 18465660

Citations 6

Authors

Xuming Mao

Aimee S Payne

Affiliations

Soon will be listed here.

Abstract

Pemphigus vulgaris is an autoimmune blistering disease of the skin and mucous membranes. Despite the potentially fatal prognosis, there are currently no FDA-approved treatments specifically for pemphigus. In 2006, the FDA designated orphan drug status to mycophenolate mofetil for the treatment of pemphigus vulgaris, indicating both federal and commercial interest in developing therapies for this devastating disease. This review focuses on pemphigus therapies that are currently in preclinical or clinical trials, as well as potential novel therapies based on recent advances in the understanding of the pathophysiology of this disease.

Citing Articles

Possible therapeutic target MKK3 in blister formation in pemphigus.

Kim R, Kim E, Ahn M, Choi Y, Choi H, Kim S Arch Dermatol Res. 2024; 316(7):352.

PMID: 38850415 DOI: 10.1007/s00403-024-03136-4.

What protein kinases are crucial for acantholysis and blister formation in pemphigus vulgaris? A systematic review.

Brescacin A, Baig Z, Bhinder J, Lin S, Brar L, Cirillo N J Cell Physiol. 2022; 237(7):2825-2837.

PMID: 35616233 PMC: 9540544. DOI: 10.1002/jcp.30784.

Getting Under the Skin: Targeting Cutaneous Autoimmune Disease.

Vesely M Yale J Biol Med. 2020; 93(1):197-206.

PMID: 32226348 PMC: 7087062.

Pemphigus: Current and Future Therapeutic Strategies.

Didona D, Maglie R, Eming R, Hertl M Front Immunol. 2019; 10:1418.

PMID: 31293582 PMC: 6603181. DOI: 10.3389/fimmu.2019.01418.

p38 MAPK Signaling in Pemphigus: Implications for Skin Autoimmunity.

Mavropoulos A, Orfanidou T, Liaskos C, Smyk D, Spyrou V, Sakkas L Autoimmune Dis. 2013; 2013:728529.

PMID: 23936634 PMC: 3722958. DOI: 10.1155/2013/728529.

References

Katz K, Hivnor C, Geist D, Shapiro M, Ming M, Werth V . Stroke and deep venous thrombosis complicating intravenous immunoglobulin infusions. Arch Dermatol. 2003; 139(8):991-3. DOI: 10.1001/archderm.139.8.991. View

Lin M, Hsu C, Lee J . Successful treatment of recalcitrant pemphigus vulgaris and pemphigus vegetans with etanercept and carbon dioxide laser. Arch Dermatol. 2005; 141(6):680-2. DOI: 10.1001/archderm.141.6.680. View

Werth V, Fivenson D, Pandya A, Chen D, Rico M, Albrecht J . Multicenter randomized, double-blind, placebo-controlled, clinical trial of dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris. Arch Dermatol. 2008; 144(1):25-32. PMC: 7382893. DOI: 10.1001/archderm.144.1.25. View

Feliciani C, Toto P, Amerio P, Pour S, Coscione G, Shivji G . In vitro and in vivo expression of interleukin-1alpha and tumor necrosis factor-alpha mRNA in pemphigus vulgaris: interleukin-1alpha and tumor necrosis factor-alpha are involved in acantholysis. J Invest Dermatol. 2000; 114(1):71-7. DOI: 10.1046/j.1523-1747.2000.00835.x. View

Warren S, Lin M, Giudice G, Hoffmann R, Hans-Filho G, Aoki V . The prevalence of antibodies against desmoglein 1 in endemic pemphigus foliaceus in Brazil. Cooperative Group on Fogo Selvagem Research. N Engl J Med. 2000; 343(1):23-30. DOI: 10.1056/NEJM200007063430104. View

Chernyavsky A, Arredondo J, Piser T, Karlsson E, Grando S . Differential coupling of M1 muscarinic and alpha7 nicotinic receptors to inhibition of pemphigus acantholysis. J Biol Chem. 2007; 283(6):3401-3408. DOI: 10.1074/jbc.M704956200. View

Olszewska M, Kolacinska-Strasz Z, Sulej J, Labecka H, Cwikla J, Natorska U . Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris. Am J Clin Dermatol. 2007; 8(2):85-92. DOI: 10.2165/00128071-200708020-00004. View

Wucherpfennig K, Yu B, Bhol K, Monos D, Argyris E, Karr R . Structural basis for major histocompatibility complex (MHC)-linked susceptibility to autoimmunity: charged residues of a single MHC binding pocket confer selective presentation of self-peptides in pemphigus vulgaris. Proc Natl Acad Sci U S A. 1995; 92(25):11935-9. PMC: 40518. DOI: 10.1073/pnas.92.25.11935. View

Messer G, Sizmann N, Feucht H, Meurer M . High-dose intravenous immunoglobulins for immediate control of severe pemphigus vulgaris. Br J Dermatol. 1995; 133(6):1014-6. DOI: 10.1111/j.1365-2133.1995.tb06952.x. View

10.

Reuther L, Vainer B, Sonne J, Larsen N . Thiopurine methyltransferase (TPMT) genotype distribution in azathioprine-tolerant and -intolerant patients with various disorders. The impact of TPMT genotyping in predicting toxicity. Eur J Clin Pharmacol. 2003; 59(11):797-801. DOI: 10.1007/s00228-003-0698-8. View

11.

Fabian M, Biggs 3rd W, Treiber D, Atteridge C, Azimioara M, Benedetti M . A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol. 2005; 23(3):329-36. DOI: 10.1038/nbt1068. View

12.

ONeill L . Targeting signal transduction as a strategy to treat inflammatory diseases. Nat Rev Drug Discov. 2006; 5(7):549-63. DOI: 10.1038/nrd2070. View

13.

Wolf R, Tuzun B, Tuzun Y . Dapsone: unapproved uses or indications. Clin Dermatol. 2000; 18(1):37-53. DOI: 10.1016/s0738-081x(99)00093-0. View

14.

Bystryn J, Jiao D . IVIg selectively and rapidly decreases circulating pathogenic autoantibodies in pemphigus vulgaris. Autoimmunity. 2006; 39(7):601-7. DOI: 10.1080/08916930600972016. View

15.

Berkowitz P, Diaz L, Hall R, Rubenstein D . Induction of p38MAPK and HSP27 phosphorylation in pemphigus patient skin. J Invest Dermatol. 2007; 128(3):738-40. DOI: 10.1038/sj.jid.5701080. View

16.

Sandborn W . Preventing antibodies to infliximab in patients with Crohn's disease: optimize not immunize. Gastroenterology. 2003; 124(4):1140-5. DOI: 10.1053/gast.2003.50182. View

17.

Liu Z, Li N, Diaz L . Inhibition of pemphigus vulgaris by targeting of the CD40-CD154 co-stimulatory pathway: a step toward antigen-specific therapy?. J Invest Dermatol. 2006; 126(1):11-3. DOI: 10.1038/sj.jid.5700059. View

18.

Pfutze M, Niedermeier A, Hertl M, Eming R . Introducing a novel Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) in pemphigus. Eur J Dermatol. 2007; 17(1):4-11. DOI: 10.1684/ejd.2007.0090. View

19.

Boucher G, Broly H, Lemieux R . Restricted use of cationic germline V(H) gene segments in human Rh(D) red cell antibodies. Blood. 1997; 89(9):3277-86. View

20.

Murrell D, Dick S, Ahmed A, Amagai M, Barnadas M, Borradori L . Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol. 2008; 58(6):1043-6. PMC: 2829665. DOI: 10.1016/j.jaad.2008.01.012. View